四环医药
SihuanPharm

Sihuan Pharmaceutical Holdings Group Ltd.
四環醫藥控股集團有限公司
(incorporated in Bermuda with limited liability)
(Stock Code: 0460)

Voluntary Announcement

CFDA Granted Full Approval of Phase I/II/III Clinical Trials for Pirotinib, an Internally Developed Innovative Patented Oncology Drug

The board of directors (the "**Board**") of Sihuan Pharmaceutical Holdings Group Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") announced that the China Food and Drug Administration (CFDA) has granted full approval of Phase I/II/III clinical trials of Pirotinib ("**Pirotinib**" or the "**new drug**"), the innovative patented oncology drug successfully developed by Shandong XuanZhu Pharma Co., Ltd. ("**Shandong XuanZhu**"), a wholly-owned subsidiary of the Group, on 7 August 2015 after the accelerated approval process. This is another major milestone after Phase I clinical trial of the new drug has been successfully initiated in the U.S.

Pirotinib, a novel irreversible pan-epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), will be studied for the treatment of lung cancer, gastric cancer as well as other malignancies with unmet medical needs. Meanwhile, the latest studies identified certain types of oncogenic mutations in the EGFR family as the possible origins of resistance to current therapies treating lung cancer, gastric cancer, esophageal cancer and other malignant tumors. However, Pirotinib is potentially effective in treating cancers with such mutations.

The Investigational New Drug (IND) application for clinical trial approval (Category 1.1) of Pirotinib to the CFDA was filed on 30 September 2013. Meanwhile, the IND application was submitted to the U.S. Food and Drug Administration (U.S. FDA) on 27 October 2014 (U.S. Time), and the clinical trial approval was granted by the U.S.

FDA on 26 November 2014 (U.S. Time). Currently, Phase I clinical trial of Pirotinib are ongoing simultaneously in three well-known cancer research centers in the U.S. and have completed the first two cohort groups, and are currently in the third cohort group in dose escalation. Patients currently taking Pirotinib have demonstrated good pharmacokinetic profiles and preliminary efficacy responses, without serious adverse effects.

Shandong XuanZhu is working closely with Covance Inc. ("**Covance**") on the clinical development of Pirotinib in China. We expect clinical trial for Pirotinib to initiate first-in-patient in China in October 2015 as planned.

The full approval of Phase I/II/III clinical trial granted by CFDA suggests not only a significant simplification of regulatory process, but also a benefit to the clinical trial for the new drug in harmonization of the Chinese and international clinical centers. This innovative model of global multi-center clinical trial led by China will help to accelerate the new drug clinical trial development globally, save time and costs, and showcase its innovative edge.

The successful IND submission of the new drug both in China and the U.S. marks the Group's entry into a new territory of oncology drug discovery and development. In addition, it showcases that the Group's research and development capabilities have been further enhanced.

This announcement is being made by the Company on a voluntary basis to let the investing public understand the Group's latest business development, and does not constitute, and is not intended to be, an advertisement regarding the use of any medicine, surgical appliance, treatment or orally consumed product.

By order of the Board
Sihuan Pharmaceutical Holdings Group Ltd.
Che Fengsheng
Chairman and Executive Director

Hong Kong, 10 August, 2015

As at the date of this announcement, the executive directors of the Company are Dr. Che Fengsheng (Chairman), Dr. Guo Weicheng (Deputy Chairman and Chief Executive Officer) and Mr. Meng Xianhui; the non-executive directors of the Company are Dr. Zhang Jionglong and Mr. Homer Sun; and the independent non-executive directors of the Company are Mr. Patrick Sun, Mr. Tsang Wah Kwong and Mr. Zhu Xun.